Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242451 | 0.88 | SLC6A4 (0.58) | SLC6A9SLC6A4HRH3SLC6A2 | |
| SCHEMBL684950 | 0.79 | SLC6A9 (0.62) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL685403 | 0.76 | SLC6A4 (0.48) | SLC6A9SLC6A4HRH3HTR1ASLC6A2 | |
| SCHEMBL13996199 | 0.75 | SLC6A4 (0.52) | SLC6A9SLC6A4HRH3SLC6A2 | |
| SCHEMBL686976 | 0.74 | SLC6A4 (0.51) | SLC6A9SLC6A4HRH3SLC6A2 | |
| SCHEMBL12677299 | 0.74 | SLC6A4 (0.51) | SLC6A9SLC6A4HRH3SLC6A2 | |
| SCHEMBL685134 | 0.72 | SLC6A4 (0.70) | SLC6A9SLC6A4HRH3SLC6A2 | |
| SCHEMBL1582713 | 0.70 | SLC6A9 (0.58) | SLC6A9SLC6A4HRH3HTR1A | |
| SCHEMBL685401 | 0.69 | SLC6A9 (0.67) | SLC6A9SLC6A4HRH3 | |
| SCHEMBL17280824 | 0.69 | SLC6A4 (0.58) | SLC6A9SLC6A4HRH3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-01-12 | — | — | US | disclosed |
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2015-05-21 | — | — | US | disclosed |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC6A9 4130/4885SLC6A4 978/4885HRH3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.